Holen Sie sich die Stockscreener-App
10.68
4.30%
-0.48
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (NASDAQ:ALMS) Trading Down 4.8% - MarketBeat
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com South Africa
Alumis reports progress in psoriasis treatment trial - Investing.com India
Alumis reports progress in psoriasis treatment trial By Investing.com - Investing.com Canada
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study - The Manila Times
ALMSAlumis Inc. Latest Stock News & Market Updates - StockTitan
Alumis (NASDAQ:ALMS) Trading Up 4.8% - MarketBeat
(ALMS) Technical Data - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - Defense World
Alumis (NASDAQ:ALMS) Shares Gap Down to $11.86 - MarketBeat
Yu Fan Purchases New Stake in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. [ALMS] Stock bought by Insider Foresite Labs, LLC for $40.0 million - Knox Daily
Taking on analysts’ expectations and winning: Alumis Inc. (ALMS) - SETE News
SR One Capital Management LP Invests $26.07 Million in Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Down 2.6% - MarketBeat
Alumis (NASDAQ:ALMS) Trading 5.3% Higher - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Up 5.3% - Defense World
Alumis (NASDAQ:ALMS) Reaches New 12-Month Low at $10.37 - MarketBeat
Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases (NASDAQ:ALMS) - Seeking Alpha
Vatroslav Mateljic Appointed General Manager of Takeda Canada - Quantisnow
Objective long/short (ALMS) Report - Stock Traders Daily
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - Reuters
Alumis (NASDAQ:ALMS) Shares Up 8.6% - MarketBeat
Alumis (NASDAQ:ALMS) Stock Price Down 4.6% - MarketBeat
Psoriasis Market is anticipated to rise at a notable CAGR, estimates DelveInsight | Hangzhou Highlightll Pharmaceutical Co., Ltd, Biohaven Pharmaceuticals, Inc., SFA Therapeutics, Bristol-Myers Squibb - Barchart
Biotech IPO Hopefuls Ready Burst of Debuts After Rough Stretch - BNN Bloomberg
Alumis (NASDAQ:ALMS) Shares Gap Up to $12.20 - MarketBeat
Alumis to Participate in Upcoming September Investor Conferences - ForexTV.com
Understanding the Risks of Investing in Alumis Inc. (ALMS) - Knox Daily
Recent Insider Activity Suggests Potential Gains for Sezzle Inc. (SEZL) - Knox Daily
(ALMS) On The My Stocks Page - Stock Traders Daily
Alumis (NASDAQ:ALMS) Shares Down 4.8% - Defense World
Alumis (NASDAQ:ALMS) Shares Down 4.8% - MarketBeat
Cantor Fitzgerald Equities Analysts Lift Earnings Estimates for Alumis Inc. (NASDAQ:ALMS) - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Forecasted to Earn FY2024 Earnings of ($5.67) Per Share - Defense World
Cantor Fitzgerald Reiterates Overweight Rating for Alumis (NASDAQ:ALMS) - MarketBeat
Q3 2024 EPS Estimates for Alumis Inc. Decreased by Leerink Partnrs (NASDAQ:ALMS) - MarketBeat
Alumis (NASDAQ:ALMS) Shares Gap Down to $12.54 - MarketBeat
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - BioSpace
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and - The Bakersfield Californian
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - wallstreet:online
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - ForexTV.com
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements - StockTitan
(ALMS) Trading Report - Stock Traders Daily
Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in Plaque Psoriasis - Dermatology Times
Checking in on Alumis Inc. (ALMS) after recent insiders movement - Knox Daily
Alumis Inc.'s Quiet Period Set To End on August 7th (NASDAQ:ALMS) - MarketBeat
Telomir Pharmaceuticals, Inc.’s Lock-Up Period Will Expire on August 7th (NASDAQ:TELO) - Defense World
BBB Foods Inc.’s Lock-Up Period Will Expire on August 7th (NYSE:TBBB) - Defense World
Alumis (NASDAQ:ALMS) Stock Price Down 5.9% - MarketBeat
Potential Competitor To BMS’s Sotyktu Bites The Dust - Scrip
Alumis begins phase 3 trials for psoriasis treatment ESK-001 By Investing.com - Investing.com Nigeria
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK - WICZ
Alumis begins phase 3 trials for psoriasis treatment ESK-001 - Investing.com
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis - StockTitan
Alumis (NASDAQ:ALMS) Stock Price Up 3% - MarketBeat
Brokers Set Expectations for Alumis Inc.’s FY2024 Earnings (NASDAQ:ALMS) - Defense World
Short Interest in Artemis Gold Inc. (OTCMKTS:ARGTF) Drops By 41.4% - Defense World
Analysts Issue Forecasts for Alumis Inc.'s FY2024 Earnings (NASDAQ:ALMS) - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Forecasted to Post FY2024 Earnings of ($6.20) Per Share - MarketBeat
Alumis Inc. (NASDAQ:ALMS) Forecasted to Post Q2 2024 Earnings of ($1.67) Per Share - Defense World
Recent Investment Analysts’ Ratings Changes for Alumis (ALMS) - Defense World
Alumis Inc. (ALMS) rating initates by Morgan Stanley - Knox Daily
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation - Markets Insider
Morgan Stanley starts Alumis Inc stock at Overweight, cites strong pipeline - Investing.com Canada
Alumis (NASDAQ:ALMS) Coverage Initiated at Morgan Stanley - Defense World
Morgan Stanley starts Alumis Inc stock at Overweight, cites strong pipeline - Investing.com India
Alumis (NASDAQ:ALMS) Coverage Initiated at Guggenheim - Defense World
0.05%
4.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):